C3, Equipmed sign distribution agreements
Monday, 27 October, 2003
Perth-based tissue engineering company Clinical Cell Culture (C3, ASX: CCE) has signed distribution agreements with Equipmed to distribute C3's CellSpray and ReCell products in Australia, excluding Western Australia, and New Zealand.
The ReCell agreement will be activated once TGA approval has been obtained for general marketing of the product. The agreements have three year terms and including marketing and support activities.
C3 CEO Troels Jordansen said the company was pleased to have an agreement with Equipmed, which has experience in the plastic and cosmetic surgery market and distributes tissue engineering products from international company Isolagen.
C3 is planning to expand its business internationally next year, with a European production facility in the works and sales of ReCell in 15 companies around the world expected.
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
CTA granted for CAR-T cell therapy for multiple myeloma
The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...
